BDX Becton Dickinson
- Price as of: Dec 19, 10:23 PM EST
- Medical instruments & supplies
BDX Stock Dividend DataAdd BDX to Watchlist
BDX Daily Snapshot
- Quote Time:
- Dec 19, 10:23 PM
- Today's Volume:
- Open Price:
- Day's Range:
- $139.49 - $141.44
- Previous Close:
- 52 Week Low / High:
- $105.21 - $142.56
- Percent Off 52 Week High:
BDX Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal More Dividend Growth History for BDX||10.1%||10.0%||42 years|
BDX Dividend History
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
BDX Company Profile
Becton Dickinson (BDX) is a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents. BDX is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BDX is largely affected by the success of its research and development efforts, as well as patent protection for its products. BDX has been paying dividends since 1962, and has increased them since 1972. The company is known as a dividend aristocrat, as it has been increasing dividends consecutively annually for more than 25 years. BDX pays dividends quarterly.
Becton Dickinson News
Wednesday's Analyst Moves: Whole Foods Market, Inc., DSW Inc., Hershey Co, More (WFM, DSW, HSY, More)Nov 26, 2014Before Wednesday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Oct 16, 2014Over the last month, the S&P 500 Index has shed upwards of 7%; prior to this sell-off, the S&P 500 was up just over 8% for the year. Put...
Tuesday's Analyst Moves: Time Warner Inc, Intercontinental Exchange Inc, Las Vegas Sands Corp., More (TWX, ICE, LVS, More)Oct 7, 2014Before Tuesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Monday's Analyst Moves: Oracle Corporation, Enterprise Products Partners L.P., Colgate-Palmolive Company, More (ORCL, EPD, CL, More)Oct 6, 2014Before Monday’s opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Oct 6, 2014On Sunday it was announced that medical technology company Becton Dickinson (BDX) will be acquiring CareFusion (CFN) for $58 per share in a stock...
Sep 4, 2014Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
Tuesday Analyst Moves: Johnson & Johnson, Yum! Brands, Inc., Target Corporation, More (JNJ, YUM, TGT, More)Jan 7, 2014Before Tuesday's opening bell, a number of big name dividend stocks were the subject of analyst moves. Below, we highlight the important analyst...
Becton, Dickinson and Co. Earnings Decline; Beats Estimates; Revenue Rises (BDX)Aug 1, 2013On Thursday, medical technology company Becton, Dickinson and Co. (BDX) released its third quarter earnings results, which were hurt by higher costs and increased taxes. Despite the rise in expenses, the company still beat analysts' earnings estimates by 10 cents per share. The Franklin Lakes, NJ-based company reported third quarter earnings of $301.55 million, or $1.52 per share, down from $326.87 million, or $1.59 per share. Excluding special items, earnings were $1.58 per share, beating analysts' estimate of $1.48 per share. Revenue for the quarter was $2.05 billion, up from $1.98 billion a year ago. On average, analysts expected to see revenue of $2.05 billion. Looking ahead to FY2013, earnings are expected to be between $5.65 and $5.68 per share. Adjusted earnings are expected to be between $5.72 and $5.75 per share. Analysts are estimating full year earnings of $5.74 per share. Becton, Dickinson and Co shares were mostly flat during pre-market trading Thursday. The stock is up 33% YTD. The Bottom Line Shares of Becton, Dickinson and Co. (BDX) have a 1.91% yield based on Wednesday's closing price of $103.72. Becton, Dickinson and Co. (BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
ISI Group Starts Coverage on Becton, Dickinson and Co. (BDX)Jun 25, 2013ISI Group reported on Tuesday that it has begun coverage on medical technology company, Becton, Dickinson and Co. (BDX) . The firm has begun coverage on BDX with a "Buy" rating and $106.50 price target. This price target suggests an 8% increase from the stock's current price of $97.83. An analyst from the firm commented, “we view Becton, Dickinson and Co (BDX) as a premier provider of medical devices, diagnostic instruments, and reagents to hospitals as well as pharma, academic, and clinical labs. We contend that the company's attractively diversified portfolio (Medical ~50% of revs, Diagnostics ~35% of revs and Biosciences ~15% of revs), should allow for mid single digit top-line growth over the medium-term. This will be driven mainly by new product momentum, increased leverage to the emerging markets, and continued strength in safety engineered products. With respect to new product momentum, we see several offerings that have been underappreciated by the Street including: BD Max (MDx), BD Rx (prefilled generics), Kiestra microbiology automation (MDx), Carmel closed drug transfer systems, Accuri flocytometry, and Sirigen (reagents). When combined with advancements in pen needles, we expect innovation to contribute ~250 bps to organic growth going forward. Lastly, we believe that emerging markets (~25% of revs) will continue to grow low double digits (with China up strong double digits), while safety engineered products (prevention of needle sticks) should expand in the high single digit range.” Becton, Dickinson shares were mostly flat during Tuesday morning trading. The stock is up 25% YTD. The Bottom Line Shares of Becton, Dickinson and Co. (BDX) have a 2.02% yield, based on Tuesday morning's price of $97.83. Becton, Dickinson and Co. (BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story
Early Flu Season Helps Boost Sales for Becton, Dickinson and Co. (BDX)Feb 5, 2013Global medical technology company, Becton, Dickinson and Co. (BDX) reported increased profits on Tuesday due to an early flu season. The Franklin Lakes, NJ based company reported first quarter earnings of $625.44 million, or $3.13 per share, up from $262.99 million, or $1.21 per share last year. Earnings from continuing operations came in at $1.35 per share, up from $1.14 last year, and beating analysts estimate of $1.24 per share. Revenue for the quarter came in at $1.9 billion, up 3.7% from last year, beating analysts estimate of $1.86 billion. Sales in the United States rose by 3%. International sales saw a 4.3% upside. The company reported that the early flu season had a significant impact on earnings for the quarter. Looking forward, the company expects to see FY2013 earnings in the range of $5.69 to $5.72 per share. BDX also sees sales growth of 4% to 4.5% for the year. Analysts are expecting to see earnings of $5.65 per share with $7.94 billion in revenue. Becton, Dickinson, & Co. shares were up $1.94, or 2.28% during premarket trading Tuesday. The stock has increased 6.5% in the past year. The Bottom Line Shares of BDX have a 2.33% dividend yield, based on Monday's closing price of $85.16 and the company's annualized dividend payout of $1.98 per share. Becton, Dickinson and Co.(BDX) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.Expand to read the full story